Actively Recruiting
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Led by Alnylam Pharmaceuticals · Updated on 2026-05-14
66
Participants Needed
19
Research Sites
194 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
CONDITIONS
Official Title
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS)
You will not qualify if you...
- Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening
- Has primary or secondary immune compromise at screening due to infections, medical conditions, or chronic therapies
- Has alanine aminotransferase or aspartate aminotransferase >2× upper limit of normal (ULN)
- Has an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m^2 at screening
- Has received an investigational agent within the last 1 year or 5 half-lives (if known)
- Other protocol defined inclusion / exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Clinical Trial Site
Edmonton, Canada, T6G 2B7
Actively Recruiting
2
Clinical Trial Site
Montreal, Canada, H2W 1T8
Actively Recruiting
3
Clinical Trial Site
Ottawa, Canada, K1Y4E9
Actively Recruiting
4
Clinical Trial Site
Vancouver, Canada, V6T 2B5
Actively Recruiting
5
Clinical Trial Site
Berlin, Germany, 10117
Actively Recruiting
6
Clinical Trial Site
Bochum, Germany, 44791
Actively Recruiting
7
Clinical Trial Site
Bonn, Germany, 53127
Actively Recruiting
8
Clinical Trial Site
Dresden, Germany, 01307
Actively Recruiting
9
Clinical Trial Site
Münster, Germany, 48149
Actively Recruiting
10
Clinical Trial Site
Taufkirchen, Germany, 84416
Actively Recruiting
11
Clinical Trial Site
Ulm, Germany, 89081
Actively Recruiting
12
Clinical Trial Site
Birmingham, United Kingdom, B15 2TT
Actively Recruiting
13
Clinical Trial Site
Cambridge, United Kingdom, CB2 0PY
Actively Recruiting
14
Clinical Trial Site
Cardiff, United Kingdom, CF103AX
Actively Recruiting
15
Clinical Trial Site
Glasgow, United Kingdom, G51 4TF
Actively Recruiting
16
Clinical Trial Site
Greater Manchester, United Kingdom, M13 9WL
Actively Recruiting
17
Clinical Trial Site
London, United Kingdom, WC1N 3BG
Actively Recruiting
18
Clinical Trial Site
Oxford, United Kingdom, OX3 9DU
Actively Recruiting
19
Clinical Trial Site
Plymouth, United Kingdom, PL6 8DH
Actively Recruiting
Research Team
A
Alnylam Clinical Trial Information Line
CONTACT
A
Alnylam Clinical Trial Information Line
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here